# Astera Labs, Inc.: overview

ALAB · Nasdaq · CIK 1736297 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/alab.md) · [Financials](/companies/alab/financials.md) · [Filings](/companies/alab/filings.md) · [Insiders](/companies/alab/insiders.md)

Latest reported revenue: [$392.4m](/filings/0001736297-26-000035.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001736297-26-000035).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [113](/filings/0001736297-25-000147.md) | [141 d](/filings/0001736297-26-000010.md) | [159](/filings/0001736297-26-000020.md) | [192](/filings/0001736297-26-000035.md) | [231](/filings/0001736297-25-000147.md) | [271 d](/filings/0001736297-26-000010.md) | [308](/filings/0001736297-26-000020.md) | [392](/filings/0001736297-26-000035.md) |
| Gross margin | % | [77.7%](/filings/0001736297-25-000147.md) | [74.0% d](/filings/0001736297-26-000010.md) | [74.9%](/filings/0001736297-26-000020.md) | [75.8%](/filings/0001736297-26-000035.md) | [76.2%](/filings/0001736297-25-000147.md) | [75.6% d](/filings/0001736297-26-000010.md) | [76.3%](/filings/0001736297-26-000020.md) | [73.3%](/filings/0001736297-26-000035.md) |
| Operating margin | % | [(7.9%)](/filings/0001736297-25-000147.md) | [0.1% d](/filings/0001736297-26-000010.md) | [7.1%](/filings/0001736297-26-000020.md) | [20.7%](/filings/0001736297-26-000035.md) | [24.0%](/filings/0001736297-25-000147.md) | [24.7% d](/filings/0001736297-26-000010.md) | [20.1%](/filings/0001736297-26-000020.md) | [22.7%](/filings/0001736297-26-000035.md) |
| Net margin | % | [(6.7%)](/filings/0001736297-25-000147.md) | [17.5% d](/filings/0001736297-26-000010.md) | [20.0%](/filings/0001736297-26-000020.md) | [26.7%](/filings/0001736297-26-000035.md) | [39.5%](/filings/0001736297-25-000147.md) | [16.6% d](/filings/0001736297-26-000010.md) | [26.0%](/filings/0001736297-26-000020.md) | [39.0%](/filings/0001736297-26-000035.md) |
| Diluted EPS | $ per share | [(0.05)](/filings/0001736297-25-000147.md) | not reported | [0.18](/filings/0001736297-26-000020.md) | [0.29](/filings/0001736297-26-000035.md) | [0.50](/filings/0001736297-25-000147.md) | not reported | [0.44](/filings/0001736297-26-000020.md) | [0.83](/filings/0001736297-26-000035.md) |
| Free cash flow | $m | [46.8 d](/filings/0001736297-25-000147.md) | [24.3 d](/filings/0001736297-26-000010.md) | [6.0](/filings/0001736297-26-000020.md) | [133 d](/filings/0001736297-26-000035.md) | [65.9 d](/filings/0001736297-25-000147.md) | [76.6 d](/filings/0001736297-26-000010.md) | [67.0](/filings/0001736297-26-000020.md) | [67.2 d](/filings/0001736297-26-000035.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2022-12-31) | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $m | [79.9](/filings/0001736297-25-000003.md) | [116](/filings/0001736297-26-000010.md) | [396](/filings/0001736297-26-000010.md) | [853](/filings/0001736297-26-000010.md) |
| Gross margin | % | [73.5%](/filings/0001736297-25-000003.md) | [68.9%](/filings/0001736297-26-000010.md) | [76.4%](/filings/0001736297-26-000010.md) | [75.7%](/filings/0001736297-26-000010.md) |
| Operating margin | % | [(75.4%)](/filings/0001736297-25-000003.md) | [(25.5%)](/filings/0001736297-26-000010.md) | [(29.3%)](/filings/0001736297-26-000010.md) | [20.3%](/filings/0001736297-26-000010.md) |
| Net margin | % | [(73.0%)](/filings/0001736297-25-000003.md) | [(22.7%)](/filings/0001736297-26-000010.md) | [(21.1%)](/filings/0001736297-26-000010.md) | [25.7%](/filings/0001736297-26-000010.md) |
| Diluted EPS | $ per share | [(1.71)](/filings/0001736297-25-000003.md) | [(0.71)](/filings/0001736297-26-000010.md) | [(0.64)](/filings/0001736297-26-000010.md) | [1.22](/filings/0001736297-26-000010.md) |
| Free cash flow | $m | [(39.8)](/filings/0001736297-25-000003.md) | [(15.5)](/filings/0001736297-26-000010.md) | [102](/filings/0001736297-26-000010.md) | [282](/filings/0001736297-26-000010.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/alab/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $12.00bn | 24,845,364 |  | Reduced −684,521 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $6.61bn | 13,683,865 |  | Added +2,234,096 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $3.81bn | 7,887,650 |  | Added +577,872 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $3.25bn | 6,727,089 |  | Added +386,357 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $2.37bn | 4,910,555 |  | Added +4,540,375 |
| [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $1.88bn | 3,896,100 | Call | Added +97,100 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $1.78bn | 3,678,093 |  | Added +344,487 |
| [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $1.40bn | 2,890,800 | Put | Added +499,000 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.35bn | 2,796,173 |  | Added +287,909 |
| [VAN ECK ASSOCIATES CORP](/funds/869178.md) | 2026-06-30 | $1.08bn | 2,237,961 |  | Added +373,545 |

## Recent filings

[All 411 filings](/companies/alab/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-05 | 21:34 ET | [10-Q](/filings/0001736297-26-000035.md) | Quarterly report, period 2026-06-30 | 0001736297-26-000035 |
| 2026-08-04 | 20:09 ET | [8-K](/filings/0001736297-26-000033.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001736297-26-000033 |
| 2026-06-08 | 21:07 ET | [8-K](/filings/0001736297-26-000027.md) | 5.07 Shareholder vote results | 0001736297-26-000027 |
| 2026-05-06 | 21:38 ET | [10-Q](/filings/0001736297-26-000020.md) | Quarterly report, period 2026-03-31 | 0001736297-26-000020 |
| 2026-05-05 | 20:11 ET | [8-K](/filings/0001736297-26-000017.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001736297-26-000017 |
| 2026-04-23 | 20:05 ET | [DEF 14A](/filings/0001140361-26-016359.md) | Proxy statement, period 2026-06-04 | 0001140361-26-016359 |
| 2026-02-20 | 22:26 ET | [10-K](/filings/0001736297-26-000010.md) | Annual report, period 2025-12-31 | 0001736297-26-000010 |
| 2026-02-10 | 21:24 ET | [8-K](/filings/0001104659-26-012649.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-26-012649 |
| 2026-02-10 | 21:09 ET | [8-K](/filings/0001736297-26-000005.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001736297-26-000005 |
| 2026-02-10 | 21:03 ET | [8-K](/filings/0001104659-26-012606.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001104659-26-012606 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001736297-26-000010.md), filed Feb 20, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/4e11a9ba-72b2-4567-9057-327ba110466d)

## About the filer

- CIK: 1736297
- Tickers: ALAB
- Exchange: Nasdaq
- SIC code: 3674 Semiconductors & Related Devices
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.